Immunotherapy of Glioblastoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (16 August 2025) | Viewed by 904
Special Issue Editor
Special Issue Information
Dear Colleagues,
Glioblastoma (GBM) is the most common malignant brain tumor in adults with poor survival. Though immunotherapy has already been successfully used to treat several distinct cancer types and several promising clinic trials are ongoing, there is no clinically successful immunotherapy treatment option for GBM. Existing in an immune-privileged central nervous system (CNS) site, GBM is considered a ‘cold tumor’ due to anatomic features including the blood–brain barrier, unclear secondary lymphoid organs, and antigen-presenting pathway. From an intra-tumoral perspective, GBM exhibits low tumor mutational burden, high molecularly heterogeneity, low lymphocyte infiltration, and a high abundance of myeloid-derived suppressor cells in tumors, among other features that might contribute to the lack of response for immunotherapy. Understanding these unique immune aspects of GBM is crucial for developing novel immunotherapeutic approaches.
For all these reasons, we believe that this Special Issue will be of great interest to professionals dedicated to studying the molecular and cellular basis of the GBM immune environment, developing the GBM immunotherapy preclinical model, as well as exploring novel translational approaches. Papers related to these areas are welcome to be submitted to this Special Issue.
Dr. Mao Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioblastoma
- immunotherapy
- antigen presentation
- CNS lymphatic system
- adoptive cell therapy
- cancer vaccine
- checkpoint blockage
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
